Matsuda N, et al. - In this single-arm, open-label trial, researchers investigated the safety and efficacy of the anti-epidermal growth factor receptor (EGFR) antibody panitumumab plus neoadjuvant chemotherapy in women with primary human epidermal growth factor receptor 2 (HER2)-negative inflammatory breast cancer (IBC). This combination of panitumumab and chemotherapy showed pathologic complete response (pCR) rates of 14% in patients with HER2-negative, hormone receptor–positive disease and 42% in patients with triple-negative IBC (the highest pCR rate ever reported in triple-negative IBC). Hence, the findings supported this combination as significantly efficacious, particularly in patients with triple-negative IBC.